NeurologyWire

FDA Approves Migraine Drug For Pediatric Patients

From NeurologyWire

FDA has approved Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.It is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medi...

Login to read story

Friday, May 22, 2015

Show last days of articles

Tool May Help MS Patients Assess Voice Quality

From NeurologyWire

The Voice Handicap Index (VHI) is an effective tool to assess patient self-perception of voice quality among MS patients (Int Arch Otorhinolaryngol. 2...Full story

Review Confirms Small Cardiovascular Risk with Daily Doses o...

From NeurologyWire

A European medicine regulatory body has updated its position on high-dose ibuprofen, saying there is a small increased risk of cardiovascular problems...Full story

SWI Shows Promise for In-Vivo Study of EAE and MS

From NeurologyWire

Researchers may be closer to using susceptibility-weighted imaging (SWI) to investigate the contribution of vascular-based hypointensities in experime...Full story

Antiplatelet Therapy and Lacunar Stroke: Still a Match

From NeurologyWire

Antiplatelet monotherapy is effective for stroke prevention in patients who have suffered lacunar stroke, and there currently exists no role for long-...Full story

Rheumatoid Arthritis Drug Meets Phase III Endpoints

From NeurologyWire

Regeneron Pharmaceuticals and Sanofi said its Phase III study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary...Full story

Wednesday, May 20, 2015

Lacunar Strokes and Antiplatelet Therapy: Is it a Match?

From NeurologyWire

Antiplatelet monotherapy is effective for stroke prevention in patients who have suffered lacunar stroke, and there currently exists no role for long-...Full story

Migraine, Estrogen And Menstruation: Information And Tips Fr...

From NeurologyWire

A series of articles to help women with migraine better understand the interaction between hormones and migraine attacks and treatment strategies for...Full story

Study Finds Men and Women With Parkinson's Differed in Nonmo...

From NeurologyWire

An analysis revealed notable sex differences in several nonmotor features of patients with newly diagnosed Parkinson's. The research was published in ...Full story

Tuesday, May 19, 2015

Phase III Trial Begins for Mild Alzheimer's Drug

From NeurologyWire

The first patients have enrolled in STEADFAST, a Phase III placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Gly...Full story

Genzyme to Collaborate with Ablynx on Multiple Sclerosis Res...

From NeurologyWire

Ablynx has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate Nanobodies against a target that plays an i...Full story

Monday, May 18, 2015

Shift Work Can Cause Sleep Problems, Weight Gain

From NeurologyWire

A new study from the University of Wisconsin School of Medicine and Public Health determined that employees who work shifts outside of a 9-to-5 schedu...Full story

Friday, May 15, 2015

Occipital Nerve Stimulation Maintains Effectiveness for Year...

From NeurologyWire

Cluster headache is considered one of the most painful and disabling primary headaches. About 1015 percent of these patients develop the chronic form,...Full story

FDA Approves Migraine Drug For Pediatric Patients

From NeurologyWire

FDA has approved Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migrain...Full story

Do Blue-light Blocking Glasses Help Migraine Patients?

From NeurologyWire

Though blue-light blocking eyeglasses have come into widespread use in Japan, their daytime use does not appear to reduce headache attacks in migraine...Full story

Experimental Migraine Drug AMG 334 Reaches Primary Endpoint

From NeurologyWire

Amgen presented the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and safety of AMG 334 for th...Full story